{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:44:03Z","timestamp":1777945443458,"version":"3.51.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Anusandhan National Research Foundation (ANRF) [earlier Science and Engineering Research Board (SERB)], Department of Science and Technology, Govt. of India","award":["EEQ\/2023\/000014"],"award-info":[{"award-number":["EEQ\/2023\/000014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11812-z","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:18:36Z","timestamp":1777709916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of protein prenylation in kidney diseases: Molecular basis and therapeutic implications"],"prefix":"10.1007","volume":"53","author":[{"given":"Rohan","family":"Bhadange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-5504","authenticated-orcid":false,"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"3","key":"11812_CR1","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK et al (2024) An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Global Health 12(3):e382\u2013e395","journal-title":"Lancet Global Health"},{"issue":"1","key":"11812_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ekir.2023.10.006","volume":"9","author":"T Tarun","year":"2024","unstructured":"Tarun T et al (2024) Updates on new therapies for patients with CKD. Kidney Int Rep 9(1):16\u201328","journal-title":"Kidney Int Rep"},{"key":"11812_CR3","doi-asserted-by":"publisher","first-page":"1238706","DOI":"10.3389\/fphar.2023.1238706","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu Z et al (2023) Functioning and mechanisms of PTMs in renal diseases. Front Pharmacol 14:1238706","journal-title":"Front Pharmacol"},{"key":"11812_CR4","doi-asserted-by":"crossref","unstructured":"Bhadange R, Gaikwad AB (2025) Unlocking new frontiers in kidney diseases: targeting endothelial dysfunction with emerging biomarkers and therapies. Drug Discovery Today, 30:104432","DOI":"10.1016\/j.drudis.2025.104432"},{"issue":"12","key":"11812_CR5","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1021\/acs.jnatprod.8b00434","volume":"81","author":"E-S Kim","year":"2018","unstructured":"Kim E-S et al (2018) Total synthesis and biological evaluation of sericetin for protection against cisplatin-induced acute kidney injury. J Nat Prod 81(12):2647\u20132653","journal-title":"J Nat Prod"},{"issue":"14","key":"11812_CR6","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1021\/acs.jmedchem.1c00410","volume":"64","author":"E Gendaszewska-Darmach","year":"2021","unstructured":"Gendaszewska-Darmach E, Garstka MA, B\u0142a\u017cewska KM (2021) Targeting small GTPases and their prenylation in diabetes mellitus. J Med Chem 64(14):9677\u20139710","journal-title":"J Med Chem"},{"key":"11812_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.yjmcc.2019.11.146","volume":"138","author":"J Gao","year":"2020","unstructured":"Gao J et al (2020) The involvement of post-translational modifications in cardiovascular pathologies: focus on SUMOylation, neddylation, succinylation, and prenylation. J Mol Cell Cardiol 138:49\u201358","journal-title":"J Mol Cell Cardiol"},{"key":"11812_CR8","doi-asserted-by":"publisher","first-page":"114915","DOI":"10.1016\/j.biopha.2023.114915","volume":"164","author":"D Jung","year":"2023","unstructured":"Jung D, Bachmann HS (2023) Regulation of protein prenylation. Biomed Pharmacother 164:114915","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"11812_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1007\/s12035-020-01870-0","volume":"57","author":"JM Reddy","year":"2020","unstructured":"Reddy JM et al (2020) Regulation of small GTPase prenylation in the nervous system. Mol Neurobiol 57(5):2220\u20132231","journal-title":"Mol Neurobiol"},{"key":"11812_CR10","doi-asserted-by":"publisher","first-page":"1410874","DOI":"10.3389\/fopht.2024.1410874","volume":"4","author":"S Ashok","year":"2024","unstructured":"Ashok S, Ramachandra Rao S (2024) Updates on protein-prenylation and associated inherited retinopathies. Front Ophthalmol 4:1410874","journal-title":"Front Ophthalmol"},{"issue":"16","key":"11812_CR11","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1002\/anie.201900585","volume":"59","author":"JL Gray","year":"2020","unstructured":"Gray JL, von Delft F, Brennan PE (2020) Targeting the small GTPase superfamily through their regulatory proteins. Angew Chem Int Ed 59(16):6342\u20136366","journal-title":"Angew Chem Int Ed"},{"key":"11812_CR12","doi-asserted-by":"publisher","first-page":"685135","DOI":"10.3389\/fmolb.2021.685135","volume":"8","author":"AC Brandt","year":"2021","unstructured":"Brandt AC, Koehn OJ, Williams CL (2021) SmgGDS: an emerging master regulator of prenylation and trafficking by small GTPases in the Ras and Rho families. Front Mol Biosci 8:685135","journal-title":"Front Mol Biosci"},{"issue":"1","key":"11812_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/cells10010066","volume":"10","author":"R Pradhan","year":"2021","unstructured":"Pradhan R et al (2021) Rho GTPases as key molecular players within intestinal mucosa and GI diseases. Cells 10(1):66","journal-title":"Cells"},{"issue":"1","key":"11812_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/21541248.2021.1932402","volume":"13","author":"C Steichen","year":"2022","unstructured":"Steichen C et al (2022) Rho GTPases in kidney physiology and diseases. Small GTPases 13(1):141\u2013161","journal-title":"Small GTPases"},{"issue":"7","key":"11812_CR15","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.3390\/ijms22073656","volume":"22","author":"K Asano-Matsuda","year":"2021","unstructured":"Asano-Matsuda K et al (2021) Role of Rho GTPase interacting proteins in subcellular compartments of podocytes. Int J Mol Sci 22(7):3656","journal-title":"Int J Mol Sci"},{"issue":"2","key":"11812_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.kint.2020.08.035","volume":"99","author":"J Matsuda","year":"2021","unstructured":"Matsuda J et al (2021) Rho GTPase regulatory proteins in podocytes. Kidney Int 99(2):336\u2013345","journal-title":"Kidney Int"},{"issue":"9","key":"11812_CR17","doi-asserted-by":"publisher","first-page":"9797","DOI":"10.1096\/fj.201802489RR","volume":"33","author":"S Patel","year":"2019","unstructured":"Patel S et al (2019) Rac-GTPase promotes fibrotic TGF-\u03b21 signaling and chronic kidney disease via EGFR, p53, and Hippo\/YAP\/TAZ pathways. FASEB J 33(9):9797","journal-title":"FASEB J"},{"issue":"8","key":"11812_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41581-024-00837-x","volume":"20","author":"H Noels","year":"2024","unstructured":"Noels H et al (2024) Post-translational modifications in kidney diseases and associated cardiovascular risk. Nat Rev Nephrol 20(8):495\u2013512","journal-title":"Nat Rev Nephrol"},{"key":"11812_CR19","doi-asserted-by":"crossref","unstructured":"Saleem MA, Welsh GI (2019) Podocyte RhoGTPases: new therapeutic targets for nephrotic syndrome? F1000Res","DOI":"10.12688\/f1000research.20105.1"},{"issue":"3","key":"11812_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41419-018-0353-z","volume":"9","author":"Z Lv","year":"2018","unstructured":"Lv Z et al (2018) Podocyte-specific Rac1 deficiency ameliorates podocyte damage and proteinuria in STZ-induced diabetic nephropathy in mice. Cell Death Dis 9(3):342","journal-title":"Cell Death Dis"},{"issue":"23","key":"11812_CR21","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1128\/MCB.00730-13","volume":"33","author":"H Yu","year":"2013","unstructured":"Yu H et al (2013) Rac1 activation in podocytes induces rapid foot process effacement and proteinuria. Mol Cell Biol 33(23):4755\u20134764","journal-title":"Mol Cell Biol"},{"issue":"1","key":"11812_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41420-024-01831-9","volume":"10","author":"J Chen","year":"2024","unstructured":"Chen J et al (2024) Cellular senescence of renal tubular epithelial cells in acute kidney injury. Cell death discovery 10(1):62","journal-title":"Cell death discovery"},{"issue":"3","key":"11812_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3892\/etm.2022.11540","volume":"24","author":"X Qian","year":"2022","unstructured":"Qian X, Yang L (2022) ROCK2 knockdown alleviates LPS-induced inflammatory injury and apoptosis of renal tubular epithelial cells via the NF-\u03baB\/NLRP3 signaling pathway. Experimental Therapeutic Med 24(3):603","journal-title":"Experimental Therapeutic Med"},{"issue":"28","key":"11812_CR24","doi-asserted-by":"publisher","first-page":"2307216","DOI":"10.1002\/advs.202307216","volume":"11","author":"J Qiao","year":"2024","unstructured":"Qiao J et al (2024) Histone H3K18 and Ezrin Lactylation promote renal dysfunction in sepsis-associated acute kidney injury. Adv Sci 11(28):2307216","journal-title":"Adv Sci"},{"key":"11812_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1146\/annurev-physiol-052521-121841","volume":"84","author":"MS Balzer","year":"2022","unstructured":"Balzer MS, Rohacs T, Susztak K (2022) How many cell types are in the kidney and what do they do? Annu Rev Physiol 84:507\u2013531","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"11812_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","volume":"7","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Tang B, Zhang C (2022) Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target therapy 7(1):182","journal-title":"Signal Transduct Target therapy"},{"issue":"2","key":"11812_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","volume":"15","author":"N Jourde-Chiche","year":"2019","unstructured":"Jourde-Chiche N et al (2019) Endothelium structure and function in kidney health and disease. Nat Rev Nephrol 15(2):87\u2013108","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"11812_CR28","doi-asserted-by":"publisher","first-page":"e025119","DOI":"10.1161\/JAHA.121.025119","volume":"11","author":"M Hauke","year":"2022","unstructured":"Hauke M et al (2022) Active RhoA exerts an inhibitory effect on the homeostasis and angiogenic capacity of human endothelial cells. J Am Heart Association 11(12):e025119","journal-title":"J Am Heart Association"},{"key":"11812_CR29","doi-asserted-by":"publisher","first-page":"576463","DOI":"10.3389\/fphys.2020.576463","volume":"11","author":"L Gong","year":"2020","unstructured":"Gong L, Pan Q, Yang N (2020) Autophagy and inflammation regulation in acute kidney injury. Front Physiol 11:576463","journal-title":"Front Physiol"},{"issue":"3","key":"11812_CR30","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/ckj\/sfaa164","volume":"14","author":"SJ McWilliam","year":"2021","unstructured":"McWilliam SJ et al (2021) The complex interplay between kidney injury and inflammation. Clin Kidney J 14(3):780\u2013788","journal-title":"Clin Kidney J"},{"issue":"10","key":"11812_CR31","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00467-017-3774-5","volume":"33","author":"A Bonavia","year":"2018","unstructured":"Bonavia A, Singbartl K (2018) A review of the role of immune cells in acute kidney injury. Pediatr Nephrol 33(10):1629\u20131639","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"11812_CR32","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1038\/s41467-019-11606-x","volume":"10","author":"MK Akula","year":"2019","unstructured":"Akula MK et al (2019) Protein prenylation restrains innate immunity by inhibiting Rac1 effector interactions. Nat Commun 10(1):3975","journal-title":"Nat Commun"},{"issue":"15","key":"11812_CR33","doi-asserted-by":"publisher","first-page":"9061","DOI":"10.3390\/ijerph19159061","volume":"19","author":"S Pisanti","year":"2022","unstructured":"Pisanti S et al (2022) Prenylation defects and oxidative stress trigger the main consequences of neuroinflammation linked to mevalonate pathway deregulation. Int J Environ Res Public Health 19(15):9061","journal-title":"Int J Environ Res Public Health"},{"key":"11812_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.freeradbiomed.2020.04.016","volume":"154","author":"OE Aparicio-Trejo","year":"2020","unstructured":"Aparicio-Trejo OE et al (2020) Chronic impairment of mitochondrial bioenergetics and \u03b2-oxidation promotes experimental AKI-to-CKD transition induced by folic acid. Free Radic Biol Med 154:18\u201332","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"11812_CR35","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/antiox11071356","volume":"11","author":"M Fontecha-Barriuso","year":"2022","unstructured":"Fontecha-Barriuso M et al (2022) Tubular mitochondrial dysfunction, oxidative stress, and progression of chronic kidney disease. Antioxidants 11(7):1356","journal-title":"Antioxidants"},{"key":"11812_CR36","doi-asserted-by":"publisher","first-page":"745279","DOI":"10.3389\/fmed.2021.745279","volume":"8","author":"DL Galvan","year":"2021","unstructured":"Galvan DL, Mise K, Danesh FR (2021) Mitochondrial regulation of diabetic kidney disease. Front Med 8:745279","journal-title":"Front Med"},{"key":"11812_CR37","doi-asserted-by":"crossref","unstructured":"Viquez M et al (2025) Rac1 promotes proximal tubule kidney repair by coupling the actin cytoskeleton to mitochondrial function. In: Proceedings of the National Academy of Sciences, 122(47): p. e2504565122","DOI":"10.1073\/pnas.2504565122"},{"key":"11812_CR38","doi-asserted-by":"crossref","unstructured":"Si M et al (2025) Protein kinase ROCK1 activates mitochondrial fission linking to oxidative stress and muscle atrophy. Kidney International","DOI":"10.1016\/j.kint.2025.05.019"},{"key":"11812_CR39","doi-asserted-by":"crossref","unstructured":"Baker ML, Cantley LG (2025) Adding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury. J Clin Investig, 135(6):e188358","DOI":"10.1172\/JCI188358"},{"issue":"1","key":"11812_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.kint.2017.07.030","volume":"93","author":"S Kumar","year":"2018","unstructured":"Kumar S (2018) Cellular and molecular pathways of renal repair after acute kidney injury. Kidney Int 93(1):27\u201340","journal-title":"Kidney Int"},{"issue":"16","key":"11812_CR41","doi-asserted-by":"publisher","first-page":"8632","DOI":"10.1074\/jbc.M115.688663","volume":"291","author":"J-I Baek","year":"2016","unstructured":"Baek J-I et al (2016) Dynamin binding protein (Tuba) deficiency inhibits ciliogenesis and nephrogenesis in vitro and in vivo. J Biol Chem 291(16):8632\u20138643","journal-title":"J Biol Chem"},{"issue":"6","key":"11812_CR42","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1038\/s41401-024-01460-z","volume":"46","author":"X-q Li","year":"2025","unstructured":"Li X-q et al (2025) Neddylation of RhoA impairs its protein degradation and promotes renal interstitial fibrosis progression in diabetic nephropathy. Acta Pharmacol Sin 46(6):1692\u20131705","journal-title":"Acta Pharmacol Sin"},{"issue":"11S","key":"11812_CR43","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1681\/ASN.20223311S1424b","volume":"33","author":"F Bock","year":"2022","unstructured":"Bock F et al (2022) Rac1 promotes epithelial collecting duct repair by maintaining mitotic morphology: FR-PO369. J Am Soc Nephrol 33(11S):424","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"11812_CR44","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1007\/s11033-020-05749-0","volume":"47","author":"J Su","year":"2020","unstructured":"Su J et al (2020) Mechanism of progression of diabetic kidney disease mediated by podocyte mitochondrial injury. Mol Biol Rep 47(10):8023\u20138035","journal-title":"Mol Biol Rep"},{"issue":"12","key":"11812_CR45","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/ph13120452","volume":"13","author":"S Lehtonen","year":"2020","unstructured":"Lehtonen S (2020) Metformin protects against podocyte injury in diabetic kidney disease. Pharmaceuticals 13(12):452","journal-title":"Pharmaceuticals"},{"issue":"1","key":"11812_CR46","first-page":"1630365","volume":"2016","author":"JS Kim","year":"2016","unstructured":"Kim JS et al (2016) Secondary focal segmental glomerulosclerosis: from podocyte injury to glomerulosclerosis. Biomed Res Int 2016(1):1630365","journal-title":"Biomed Res Int"},{"issue":"11","key":"11812_CR47","doi-asserted-by":"publisher","first-page":"e80328","DOI":"10.1371\/journal.pone.0080328","volume":"8","author":"A Babelova","year":"2013","unstructured":"Babelova A et al (2013) Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease. PLoS ONE 8(11):e80328","journal-title":"PLoS ONE"},{"key":"11812_CR48","doi-asserted-by":"publisher","first-page":"118124","DOI":"10.1016\/j.biopha.2025.118124","volume":"187","author":"R Bhadange","year":"2025","unstructured":"Bhadange R, Dagar N, Gaikwad AB (2025) Levosimendan mitigates renal fibrosis via TGF-\u03b21\/Smad axis modulation in UUO rats. Biomed Pharmacother 187:118124","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"11812_CR49","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41581-022-00590-z","volume":"18","author":"L Li","year":"2022","unstructured":"Li L, Fu H, Liu Y (2022) The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol 18(9):545\u2013557","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"11812_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","volume":"8","author":"R Huang","year":"2023","unstructured":"Huang R, Fu P, Ma L (2023) Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct Target therapy 8(1):129","journal-title":"Signal Transduct Target therapy"},{"key":"11812_CR51","doi-asserted-by":"publisher","first-page":"607968","DOI":"10.3389\/fendo.2020.607968","volume":"11","author":"Y-H Wei","year":"2021","unstructured":"Wei Y-H et al (2021) Simvastatin and ROCK inhibitor Y-27632 inhibit myofibroblast differentiation of Graves\u2019 ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways. Front Endocrinol 11:607968","journal-title":"Front Endocrinol"},{"issue":"24","key":"11812_CR52","doi-asserted-by":"publisher","first-page":"e70273","DOI":"10.1111\/jcmm.70273","volume":"28","author":"GR Ross","year":"2024","unstructured":"Ross GR, Vodanovic-Jankovic S, Benjamin IJ (2024) Geranylgeranyl Pyrophosphate Promotes Profibrotic Factors and Collagen\u2010Specific Chaperone HSP47 in Fibroblasts. J Cell Mol Med 28(24):e70273","journal-title":"J Cell Mol Med"},{"key":"11812_CR53","doi-asserted-by":"crossref","unstructured":"Nagai Y et al (2019) ROCK2 regulates TGF-\u03b2-induced expression of CTGF and profibrotic genes via NF-\u03baB and cytoskeleton dynamics in mesangial cells. American Journal of Physiology-Renal Physiology","DOI":"10.2337\/db19-505-P"},{"key":"11812_CR54","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.biopha.2018.10.195","volume":"109","author":"D Sharma","year":"2019","unstructured":"Sharma D et al (2019) Kaempferol attenuates diabetic nephropathy by inhibiting RhoA\/Rho-kinase mediated inflammatory signalling. Biomed Pharmacother 109:1610\u20131619","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"11812_CR55","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1038\/s41401-024-01295-8","volume":"45","author":"A Ajoolabady","year":"2024","unstructured":"Ajoolabady A, Pratico D, Ren J (2024) Endothelial dysfunction: mechanisms and contribution to diseases. Acta Pharmacol Sin 45(10):2023\u20132031","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"11812_CR56","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0003319720987752","volume":"72","author":"P Poredos","year":"2021","unstructured":"Poredos P, Poredos AV, Gregoric I (2021) Endothelial dysfunction and its clinical implications. Angiology 72(7):604\u2013615","journal-title":"Angiology"},{"issue":"1","key":"11812_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ijms21010002","volume":"21","author":"M Aslam","year":"2019","unstructured":"Aslam M et al (2019) Inhibition of protein prenylation of GTPases alters endothelial barrier function. Int J Mol Sci 21(1):2","journal-title":"Int J Mol Sci"},{"key":"11812_CR58","doi-asserted-by":"publisher","first-page":"109625","DOI":"10.1016\/j.cbi.2021.109625","volume":"348","author":"A Shu","year":"2021","unstructured":"Shu A et al (2021) Catalpol ameliorates endothelial dysfunction and inflammation in diabetic nephropathy via suppression of RAGE\/RhoA\/ROCK signaling pathway. Chemico-Biol Interact 348:109625","journal-title":"Chemico-Biol Interact"},{"key":"11812_CR59","doi-asserted-by":"crossref","unstructured":"Liu X et al (2025) Farnesyl pyrophosphate synthase promotes restenosis afte r vascular injury by activating small G proteins. J Biol Chem, 301(12):110861","DOI":"10.1016\/j.jbc.2025.110861"},{"issue":"10","key":"11812_CR60","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.3390\/ijms23105424","volume":"23","author":"A Marchwicka","year":"2022","unstructured":"Marchwicka A et al (2022) Protein prenyltransferases and their inhibitors: structural and functional characterization. Int J Mol Sci 23(10):5424","journal-title":"Int J Mol Sci"},{"issue":"15","key":"11812_CR61","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1074\/jbc.REV119.008897","volume":"295","author":"Y Zhao","year":"2020","unstructured":"Zhao Y et al (2020) The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease. J Biol Chem 295(15):5152\u20135162","journal-title":"J Biol Chem"},{"key":"11812_CR62","doi-asserted-by":"publisher","first-page":"117417","DOI":"10.1016\/j.bmc.2023.117417","volume":"92","author":"MS Ballari","year":"2023","unstructured":"Ballari MS et al (2023) Lipophilic modification of salirasib modulates the antiproliferative and antimigratory activity. Bioorg Med Chem 92:117417","journal-title":"Bioorg Med Chem"},{"key":"11812_CR63","doi-asserted-by":"publisher","first-page":"1132355","DOI":"10.3389\/fmed.2023.1132355","volume":"10","author":"K Yang","year":"2023","unstructured":"Yang K et al (2023) Application of nanoparticles in the diagnosis and treatment of chronic kidney disease. Front Med 10:1132355","journal-title":"Front Med"},{"key":"11812_CR64","doi-asserted-by":"crossref","unstructured":"Huang H et al (2021) Farnesylthiosalicylic acid-loaded albumin nanoparticle alleviates renal fibrosis by inhibiting Ras\/Raf1\/p38 signaling pathway. Int J Nanomed,16:6441\u20136453","DOI":"10.2147\/IJN.S318124"},{"key":"11812_CR65","doi-asserted-by":"publisher","first-page":"1233322","DOI":"10.3389\/frtra.2023.1233322","volume":"2","author":"S Xu","year":"2023","unstructured":"Xu S et al (2023) Farnesyltransferase-inhibitors exert in vitro immunosuppressive capacity by inhibiting human B-cells. Front Transplantation 2:1233322","journal-title":"Front Transplantation"},{"key":"11812_CR66","doi-asserted-by":"publisher","first-page":"1678812","DOI":"10.3389\/fphar.2025.1678812","volume":"16","author":"M Wei","year":"2025","unstructured":"Wei M et al (2025) Enzymatic post-translational modifications of proteins in chronic kidney disease: mechanisms, regulation, and clinical significance. Front Pharmacol 16:1678812","journal-title":"Front Pharmacol"},{"issue":"2","key":"11812_CR67","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.tips.2024.12.008","volume":"46","author":"H Chen","year":"2025","unstructured":"Chen H et al (2025) Protein prenylation in mechanotransduction: implications for disease and therapy. Trends Pharmacol Sci 46(2):163\u2013179","journal-title":"Trends Pharmacol Sci"},{"key":"11812_CR68","doi-asserted-by":"publisher","first-page":"115566","DOI":"10.1016\/j.bone.2020.115566","volume":"141","author":"JR Center","year":"2020","unstructured":"Center JR, Lyles KW, Bliuc D (2020) Bisphosphonates Lifesp Bone 141:115566","journal-title":"Bisphosphonates Lifesp Bone"},{"key":"11812_CR69","doi-asserted-by":"publisher","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","volume":"139","author":"MJ Rogers","year":"2020","unstructured":"Rogers MJ, M\u00f6nkk\u00f6nen J, Munoz MA (2020) Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 139:115493","journal-title":"Bone"},{"key":"11812_CR70","first-page":"115407","volume":"137","author":"MR McClung","year":"2020","unstructured":"McClung MR, Ebetino FH (2020) History risedronate Bone 137:115407","journal-title":"History risedronate Bone"},{"key":"11812_CR71","doi-asserted-by":"crossref","unstructured":"Bhadange R, Gaikwad AB (2025) Repurposing the familiar: Future treatment options against chronic kidney disease. J Pharm Pharmacol,77(6):715\u2013728","DOI":"10.1093\/jpp\/rgaf002"},{"issue":"1","key":"11812_CR72","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12931-022-02274-5","volume":"23","author":"D Liu","year":"2022","unstructured":"Liu D et al (2022) Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS\/ERK\/NF-\u03baB and RhoA\/ROCK1\/MLCP signaling. Respir Res 23(1):380","journal-title":"Respir Res"},{"key":"11812_CR73","doi-asserted-by":"crossref","unstructured":"Bhadange R, Gaikwad AB (2025) Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA\/ROCK1 and ERK\/NF-\u03baB signaling. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology, pp 1\u201318","DOI":"10.1007\/s00210-025-04870-w"},{"key":"11812_CR74","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00774-018-0977-1","volume":"37","author":"T Sugimoto","year":"2019","unstructured":"Sugimoto T et al (2019) Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan. J Bone Miner Metab 37:730\u2013740","journal-title":"J Bone Miner Metab"},{"key":"11812_CR75","first-page":"115411","volume":"137","author":"SR Cummings","year":"2020","unstructured":"Cummings SR et al (2020) History alendronate Bone 137:115411","journal-title":"History alendronate Bone"},{"issue":"6","key":"11812_CR76","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00774-023-01471-6","volume":"41","author":"S Harata","year":"2023","unstructured":"Harata S et al (2023) Effects of bisphosphonates and treadmill exercise on bone and kidney in adenine-induced chronic kidney disease rats. J Bone Miner Metab 41(6):785\u2013796","journal-title":"J Bone Miner Metab"},{"key":"11812_CR77","doi-asserted-by":"crossref","unstructured":"Naganathar N et al (2021) Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice. Osteoporos 32(10):1981\u20131988","DOI":"10.1007\/s00198-021-05907-5"},{"issue":"1","key":"11812_CR78","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1186\/s12885-020-07568-9","volume":"20","author":"L Wang","year":"2020","unstructured":"Wang L et al (2020) Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer 20(1):1059","journal-title":"BMC Cancer"},{"issue":"1","key":"11812_CR79","doi-asserted-by":"publisher","first-page":"18283","DOI":"10.1038\/s41598-024-68303-z","volume":"14","author":"RH Mohamed","year":"2024","unstructured":"Mohamed RH et al (2024) The role of protein prenylation inhibition through targeting FPPS by zoledronic acid in the prevention of renal fibrosis in rats. Sci Rep 14(1):18283","journal-title":"Sci Rep"},{"key":"11812_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-021-00977-6","volume":"23","author":"M Satny","year":"2021","unstructured":"Satny M, Hubacek JA, Vrablik M (2021) Statins and inflammation. Curr Atheroscler Rep 23:1\u20138","journal-title":"Curr Atheroscler Rep"},{"issue":"5\u20136","key":"11812_CR81","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/21541248.2021.1878001","volume":"12","author":"AT Ngo","year":"2021","unstructured":"Ngo AT et al (2021) Rho GTPase regulation of reactive oxygen species generation and signalling in platelet function and disease. Small GTPases 12(5\u20136):440\u2013457","journal-title":"Small GTPases"},{"issue":"2","key":"11812_CR82","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/pharmaceutics16020214","volume":"16","author":"N Khatiwada","year":"2024","unstructured":"Khatiwada N, Hong Z (2024) Potential benefits and risks associated with the use of statins. Pharmaceutics 16(2):214","journal-title":"Pharmaceutics"},{"issue":"1","key":"11812_CR83","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/0886022X.2021.1915799","volume":"43","author":"L Zhao","year":"2021","unstructured":"Zhao L, Li S, Gao Y (2021) Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail 43(1):718\u2013728","journal-title":"Ren Fail"},{"issue":"1","key":"11812_CR84","doi-asserted-by":"publisher","first-page":"16632","DOI":"10.1038\/s41598-019-53064-x","volume":"9","author":"K Esmeijer","year":"2019","unstructured":"Esmeijer K et al (2019) Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep 9(1):16632","journal-title":"Sci Rep"},{"key":"11812_CR85","doi-asserted-by":"crossref","unstructured":"Pengrattanachot N et al (2020) Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation. Biochim. Biophys. Acta Mol. Basis Dis.1866(6):165741","DOI":"10.1016\/j.bbadis.2020.165741"},{"issue":"1","key":"11812_CR86","first-page":"179","volume":"16","author":"M Eldesoqui","year":"2024","unstructured":"Eldesoqui M et al (2024) The Renoprotective Effect of Atorvastatin in a Rat Model of High-Fat High-Fructose Diet-Induced Renal Injury. Egypt Acad J Biol Sci D Histol Histochem 16(1):179\u2013194","journal-title":"Egypt Acad J Biol Sci D Histol Histochem"},{"issue":"5","key":"11812_CR87","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/iub.2250","volume":"72","author":"Y Sun","year":"2020","unstructured":"Sun Y et al (2020) Atorvastatin inhibits renal inflammatory response induced by calcium oxalate crystals via inhibiting the activation of TLR4\/NF-\u03baB and NLRP3 inflammasome. IUBMB Life 72(5):1065\u20131074","journal-title":"IUBMB Life"},{"key":"11812_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2016.02.012","volume":"107","author":"F Cortese","year":"2016","unstructured":"Cortese F et al (2016) Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacol Res 107:1\u201318","journal-title":"Pharmacol Res"},{"issue":"4","key":"11812_CR89","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/EC9.0000000000000049","volume":"2","author":"B Zhou","year":"2022","unstructured":"Zhou B et al (2022) Rosuvastatin alleviates renal injury in cardiorenal syndrome model rats through anti-inflammatory and antioxidant pathways. Emerg Crit Care Med 2(4):203\u2013208","journal-title":"Emerg Crit Care Med"},{"issue":"12","key":"11812_CR90","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.3390\/antiox11122465","volume":"11","author":"P-H Sung","year":"2022","unstructured":"Sung P-H et al (2022) Oxidized-LDL Deteriorated the Renal Residual Function and Parenchyma in CKD Rat through Upregulating Epithelial Mesenchymal Transition and Extracellular Matrix-Mediated Tubulointerstitial Fibrosis\u2014Pharmacomodulation of Rosuvastatin. Antioxidants 11(12):2465","journal-title":"Antioxidants"},{"key":"11812_CR91","doi-asserted-by":"publisher","first-page":"122445","DOI":"10.1016\/j.lfs.2024.122445","volume":"340","author":"IH Hasan","year":"2024","unstructured":"Hasan IH et al (2024) Simvastatin mitigates diabetic nephropathy by upregulating farnesoid X receptor and Nrf2\/HO-1 signaling and attenuating oxidative stress and inflammation in rats. Life Sci 340:122445","journal-title":"Life Sci"},{"issue":"4","key":"11812_CR92","first-page":"167","volume":"43","author":"A Kafkasli","year":"2021","unstructured":"Kafkasli A, Ozkorkmaz EG (2021) Prolonged Simvastatin Treatment Provided a Decrease in Apoptotic, Inflammatory, and Oxidative Stress Markers in Ischemia-Reperfusion\u2013Induced Acute Kidney Injury Model of Rats. Anal Quant Cytopathol Histopathology 43(4):167\u2013173","journal-title":"Anal Quant Cytopathol Histopathology"},{"issue":"19","key":"11812_CR93","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3390\/ijms21197236","volume":"21","author":"L Ne\u017ei\u0107","year":"2020","unstructured":"Ne\u017ei\u0107 L et al (2020) Protective effects of simvastatin on endotoxin-induced acute kidney injury through activation of tubular epithelial cells\u2019 survival and hindering cytochrome C-mediated apoptosis. Int J Mol Sci 21(19):7236","journal-title":"Int J Mol Sci"},{"key":"11812_CR94","doi-asserted-by":"crossref","unstructured":"Elbaset MA et al (2024) Renoprotective effect of pitavastatin against TAA-induced renal injury: involvement of the miR\u201093\/PTEN\/AKT\/mTOR pathway. Adv. Pharmacol. Pharm. Sci. 2024(1):6681873","DOI":"10.1155\/2024\/6681873"},{"issue":"7","key":"11812_CR95","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/jphp.13090","volume":"71","author":"S Kaushik","year":"2019","unstructured":"Kaushik S et al (2019) Pitavastatin attenuates cisplatin-induced renal injury by targeting MAPK and apoptotic pathways. J Pharm Pharmacol 71(7):1072\u20131081","journal-title":"J Pharm Pharmacol"},{"key":"11812_CR96","unstructured":"Sizar O, Nassereddin A, Talati R (2023) Ezetimibe, in StatPearls [internet]. StatPearls Publishing"},{"issue":"4","key":"11812_CR97","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/13813455.2021.1874996","volume":"129","author":"R Nabi","year":"2023","unstructured":"Nabi R et al (2023) Ezetimibe attenuates experimental diabetes and renal pathologies via targeting the advanced glycation, oxidative stress and AGE-RAGE signalling in rats. Arch Physiol Biochem 129(4):831\u2013846","journal-title":"Arch Physiol Biochem"},{"issue":"1","key":"11812_CR98","doi-asserted-by":"publisher","first-page":"e23382","DOI":"10.1096\/fj.202302019R","volume":"38","author":"N Fathy","year":"2024","unstructured":"Fathy N et al (2024) Ezetimibe ameliorates cisplatin-induced nephrotoxicity: A novel therapeutic approach via modulating AMPK\/Nrf2\/TXNIP signaling. FASEB J 38(1):e23382","journal-title":"FASEB J"},{"issue":"3","key":"11812_CR99","doi-asserted-by":"publisher","first-page":"376","DOI":"10.17305\/bb.2022.8534","volume":"23","author":"L Jin","year":"2023","unstructured":"Jin L et al (2023) Anti-inflammatory role of fenofibrate in treating diseases. Biomolecules Biomed 23(3):376","journal-title":"Biomolecules Biomed"},{"issue":"4","key":"11812_CR100","doi-asserted-by":"publisher","first-page":"553","DOI":"10.7150\/ijbs.40643","volume":"16","author":"Y Cheng","year":"2020","unstructured":"Cheng Y et al (2020) The role of Akt2 in the protective effect of fenofibrate against diabetic nephropathy. Int J Biol Sci 16(4):553","journal-title":"Int J Biol Sci"},{"key":"11812_CR101","doi-asserted-by":"crossref","unstructured":"Tang C et al (2023) Fenofibrate attenuates renal tubular cell apoptosis by up-regulating MCAD in diabetic kidney disease. Drug design, development and therapy, pp. 1503\u20131514","DOI":"10.2147\/DDDT.S405266"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11812-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:01:57Z","timestamp":1777723317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11812-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11812"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11812-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"706"}}